← Leaderboards
Mignon Lee-Cheun Loh
University Of California San Francisco
$16,050,583
Attributed
$46,952,654
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.3M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$62,080,534 · 10
By mechanism
U24$38,672,494 · 1
P50$15,127,880 · 1
R01$3,480,276 · 1
RC2$1,708,950 · 1
RC4$1,573,220 · 1
K23$506,217 · 1
Top collaborators
- Nilsa Del Carmen Ramirez8 shared
- Stephen X Skapek8 shared
- Mary V. Relling6 shared
- Sandra Holley Thomas5 shared
- Stephen Patrick Hunger3 shared
- Charles G. Mullighan3 shared
- Michael J Borowitz2 shared
- Meenakshi Devidas2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Kevin M Shannon$44,683,939
- Anthony L. Defranco$19,534,694
- Lily Y Jan$24,385,637
- Boris C Bastian$20,025,092
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildClinical TrialsResearch PersonnelClinical ResearchLeukemiaMalignant NeoplasmsCollaborationsEnrollmentPathway InteractionsChildhoodResponseChemotherapyDiagnosisRelapseBasic ScienceAffectCommunitiesAdvocateSamplingCellsFoundationsBaseInternationalAdolescent
Grant awards (37)
COG Biospecimen Bank to Support NCI NCTN (U24)$8,404,851
U24 · FY2025 · CA
Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia$3,480,276
R01 · FY2025 · CA · contact PI
Developing Multispecific T cell Engaging Therapy for Mixed Phenotype Acute Leukemia$434,361
R21 · FY2025 · CA · contact PI
COG Biospecimen Bank to Support NCI NCTN (U24)$6,232,880
U24 · FY2024 · CA
COG Biospecimen Bank to Support NCI NCTN (U24)$3,678,162
U24 · FY2023 · CA
COG Biobanking Support$2,900,934
U24 · FY2023 · CA
COG Biospecimen Bank to Support NCI NCTN (U24)$3,411,104
U24 · FY2022 · CA
COG Relapse Tumor- Supplement$1,794,931
U24 · FY2022 · CA
COG Biospecimen Bank to Support NCI NCTN (U24)$7,636,196
U24 · FY2021 · CA
COG Biospecimen Bank to Support NCI NCTN (U24)$4,613,436
U24 · FY2020 · CA
Center for Precision Medicine in Leukemia (CPML)$2,918,766
P50 · FY2019 · GM
Center for Precision Medicine in Leukemia (CPML)$3,040,119
P50 · FY2018 · GM
Center for Precision Medicine in Leukemia (CPML)$2,964,251
P50 · FY2017 · GM
Center for Precision Medicine in Leukemia (CPML)$96,271
P50 · FY2017 · GM
Center for Precision Medicine in Leukemia (CPML)$2,969,744
P50 · FY2016 · GM
Center for Precision Medicine in Leukemia (CPML)$3,138,729
P50 · FY2015 · GM
International Symposium on Juvenile Myelomonocytic Leukemia (JMML)$5,000
R13 · FY2014 · CA
International Symposium on Juvenile Myelomonocytic Leukemia (JMML)$10,000
R13 · FY2013 · CA
International Symposium on Juvenile Myelomonocytic Leukemia (JMML)$10,000
R13 · FY2012 · CA
International Symposium on Juvenile Myelomonocytic Leukemia (JMML)$15,000
R13 · FY2011 · CA
Identifying the spectrum of genetic alterations in high risk ALL$1,573,220
RC4 · FY2010 · CA
Targeted Therapies for Childhood Acute Lymphoblastic Leukemia$876,194
RC2 · FY2010 · CA
International Symposium on Juvenile Myelomonocytic Leukeumia (JMML)$13,000
R13 · FY2010 · CA
Targeted Therapies for Childhood Acute Lymphoblastic Leukemia$832,756
RC2 · FY2009 · CA
International Symposium on Juvenile Myelomonocytic Leukemia$5,000
R13 · FY2009 · CA · contact PI
Ras Pathway Mutations in Human Leukemia$149,175
K22 · FY2008 · CA · contact PI
International Symposium on Juvenile Myelomonocytic Leukemia$27,500
R13 · FY2008 · CA · contact PI
International Symposium on Juvenile Myelomonocytic Leukemia$20,000
R13 · FY2008 · CA · contact PI
Ras Pathway Mutations in Human Leukemia$149,175
K22 · FY2007 · CA · contact PI
International Symposium on Juvenile Myelomonocytic Leukemia$7,500
R13 · FY2007 · CA · contact PI
Ras Pathway Mutations in Human Leukemia$149,175
K22 · FY2006 · CA · contact PI
OPEN LABEL, PHASE I/II TRIAL OF RITUXIMAB FOR CHRONIC, SEVERE ITP$5,504
M01 · FY2005 · RR
Open label, phase I/II trial of rituximab for chronic, severe ITP$11,107
M01 · FY2004 · RR
FUSION GENES IN LEUKEMIA--DETERMINING SIGNIFICANCE$126,792
K23 · FY2003 · CA
FUSION GENES IN LEUKEMIA--DETERMINING SIGNIFICANCE$126,570
K23 · FY2002 · CA
FUSION GENES IN LEUKEMIA--DETERMINING SIGNIFICANCE$127,166
K23 · FY2001 · CA
FUSION GENES IN LEUKEMIA--DETERMINING SIGNIFICANCE$125,689
K23 · FY2000 · CA